Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
[Display omitted] GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global d...
Saved in:
| Published in | Journal of hepatology Vol. 65; no. 6; pp. 1140 - 1147 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.12.2016
Elsevier Science Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0168-8278 1600-0641 1600-0641 |
| DOI | 10.1016/j.jhep.2016.07.020 |
Cover
| Abstract | [Display omitted]
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction.
Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up.
In the overall safety population (n=3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n=3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8–14.7]) compared with Child-Pugh B patients (5.2 [4.6–6.3]).
In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions.
The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment. |
|---|---|
| AbstractList | [Display omitted]
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction.
Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up.
In the overall safety population (n=3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n=3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8–14.7]) compared with Child-Pugh B patients (5.2 [4.6–6.3]).
In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions.
The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction. Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up. In the overall safety population (n=3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n=3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8-14.7]) compared with Child-Pugh B patients (5.2 [4.6-6.3]). In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions. The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction.BACKGROUND & AIMSGIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction.Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up.METHODSBaseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up.In the overall safety population (n=3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n=3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8-14.7]) compared with Child-Pugh B patients (5.2 [4.6-6.3]).RESULTSIn the overall safety population (n=3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n=3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8-14.7]) compared with Child-Pugh B patients (5.2 [4.6-6.3]).In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions.CONCLUSIONSIn clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions.The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment.LAY SUMMARYThe GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment. Graphical abstract Background & Aims: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction. Methods: Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up. Results: In the overall safety population (n = 3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800 mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n = 3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8–14.7]) compared with Child-Pugh B patients (5.2 [4.6–6.3]). Conclusions: In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions. Lay summary: The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment. |
| Author | Lehr, Robert Marrero, Jorge A. de Guevara, Laura Ladrón Kudo, Masatoshi Papandreou, Christos Takayama, Tadatoshi Lencioni, Riccardo Geschwind, Jean-Francois H. Bronowicki, Jean-Pierre Chen, Xiao-Ping Ye, Sheng-Long Furuse, Junji Dagher, Lucy Yoon, Seung Kew Nakajima, Keiko Venook, Alan P. Heldner, Stephanie Sanyal, Arun J. |
| Author_xml | – sequence: 1 givenname: Jorge A. surname: Marrero fullname: Marrero, Jorge A. email: jorge.marrero@utsouthwestern.edu organization: Department of Internal Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA – sequence: 2 givenname: Masatoshi surname: Kudo fullname: Kudo, Masatoshi organization: Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan – sequence: 3 givenname: Alan P. surname: Venook fullname: Venook, Alan P. organization: Medical Oncology and Translational Research, University of California, San Francisco, CA, USA – sequence: 4 givenname: Sheng-Long surname: Ye fullname: Ye, Sheng-Long organization: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China – sequence: 5 givenname: Jean-Pierre surname: Bronowicki fullname: Bronowicki, Jean-Pierre organization: University Henri Poincaré by University of Lorraine, Nancy, France – sequence: 6 givenname: Xiao-Ping surname: Chen fullname: Chen, Xiao-Ping organization: Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China – sequence: 7 givenname: Lucy surname: Dagher fullname: Dagher, Lucy organization: Policlínica Metropolitana, Caracas, Venezuela – sequence: 8 givenname: Junji surname: Furuse fullname: Furuse, Junji organization: Kyorin University School of Medicine, Mitaka, Tokyo, Japan – sequence: 9 givenname: Jean-Francois H. surname: Geschwind fullname: Geschwind, Jean-Francois H. organization: Vascular and Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 10 givenname: Laura Ladrón surname: de Guevara fullname: de Guevara, Laura Ladrón organization: Hospital Angeles Clínica Londres, Mexico City, Mexico – sequence: 11 givenname: Christos surname: Papandreou fullname: Papandreou, Christos organization: University Hospital of Larissa, Larissa, Greece – sequence: 12 givenname: Tadatoshi surname: Takayama fullname: Takayama, Tadatoshi organization: Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan – sequence: 13 givenname: Arun J. surname: Sanyal fullname: Sanyal, Arun J. organization: Virginia Commonwealth University Medical Center, Richmond, VA, USA – sequence: 14 givenname: Seung Kew surname: Yoon fullname: Yoon, Seung Kew organization: The Catholic University of Korea, Seoul, Republic of Korea – sequence: 15 givenname: Keiko surname: Nakajima fullname: Nakajima, Keiko organization: Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Inc., Montville, NJ, USA – sequence: 16 givenname: Robert surname: Lehr fullname: Lehr, Robert organization: Clinical Statistics, Bayer HealthCare Pharmaceuticals, Inc., Montville, NJ, USA – sequence: 17 givenname: Stephanie surname: Heldner fullname: Heldner, Stephanie organization: Global Medical Affairs and Pharmacovigilance, Bayer HealthCare Pharmaceuticals, Inc., Berlin, Germany – sequence: 18 givenname: Riccardo surname: Lencioni fullname: Lencioni, Riccardo organization: Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27469901$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNksFu1DAQhi1URLeFF-CALHHhkmVsp7FTISS0LaVSxSJRzpbjTHYdsklqJ0V5-3q7bQ8rUTjZkr9_PPpmjshB27VIyFsGcwYs-1jP6zX2cx7vc5Bz4PCCzFgGkECWsgMyiw8qUVyqQ3IUQg0AAvL0FTnkMs3yHNiM1MsioL81g-ta01CPKxcGP9GuoqHzpsLWFXQMSF1LbeNaZyPVe2MHZ5Ea67sQ6GLtmjL5Ma7WNIzFyndjH07p9RrpxeXZ-fI7DcNYTq_Jy8o0Ad88nMfk19fz68W35Gp5cbn4cpXY2PqQ5IJbphiWRW5LBGs5KwRXAk4qpayQuZRSmcgKSAsJaLCQxvAyRcZZJpQ4JmJXd2x7M_0xTaN77zbGT5qB3prTtd6a01tzGqSO5mLqwy7V--5mxDDojQsWm8a02I1BM8UzKaTkLKLv99C6G33UF2JFqRQTIj-J1LsHaiw2WD718Og-AnwH3Ev0WP1fm2ovZN1wP73BG9c8H_20i2KUf-vQ62AdthZL59EOuuzc8_HPe_HHffiNE4YnBUwHrkH_3C7fdvfiTECkWRoLnP69wL9-vwPaoeb8 |
| CitedBy_id | crossref_primary_10_1097_HEP_0000000000001229 crossref_primary_10_18632_oncotarget_21401 crossref_primary_10_1007_s00259_022_05920_8 crossref_primary_10_1007_s00432_018_2610_z crossref_primary_10_1038_s43018_022_00357_2 crossref_primary_10_1080_21655979_2021_2001239 crossref_primary_10_1001_jamaoncol_2023_3284 crossref_primary_10_1111_liv_14941 crossref_primary_10_3389_fmolb_2021_618050 crossref_primary_10_1186_s40164_018_0109_6 crossref_primary_10_1111_liv_14270 crossref_primary_10_12688_f1000research_145493_2 crossref_primary_10_12688_f1000research_145493_1 crossref_primary_10_3748_wjg_v26_i16_1888 crossref_primary_10_1055_a_2189_6353 crossref_primary_10_1016_j_jfma_2019_09_003 crossref_primary_10_1159_000505692 crossref_primary_10_2147_CMAR_S216220 crossref_primary_10_1002_cld_782 crossref_primary_10_1016_j_jhep_2017_03_007 crossref_primary_10_1016_j_dld_2020_12_001 crossref_primary_10_1016_j_jhep_2020_11_026 crossref_primary_10_1016_j_cld_2020_07_012 crossref_primary_10_1111_apt_15336 crossref_primary_10_1016_j_cld_2020_07_011 crossref_primary_10_1155_2021_6640121 crossref_primary_10_3390_livers2040024 crossref_primary_10_1007_s00432_023_04590_9 crossref_primary_10_1002_cncr_30863 crossref_primary_10_1111_apt_15573 crossref_primary_10_1038_s41416_021_01535_2 crossref_primary_10_4251_wjgo_v14_i8_1510 crossref_primary_10_1016_j_jfma_2020_10_031 crossref_primary_10_5009_gnl19024 crossref_primary_10_1016_j_crad_2021_03_022 crossref_primary_10_1016_j_ejrad_2017_10_017 crossref_primary_10_1016_j_dld_2022_08_032 crossref_primary_10_1080_14737140_2023_2181162 crossref_primary_10_1007_s11523_017_0484_7 crossref_primary_10_1371_journal_pone_0184597 crossref_primary_10_2217_hep_2023_0002 crossref_primary_10_1007_s11523_019_00624_w crossref_primary_10_1159_000534127 crossref_primary_10_3390_curroncol30010038 crossref_primary_10_3390_livers3010011 crossref_primary_10_3390_curroncol30100633 crossref_primary_10_1159_000515490 crossref_primary_10_1016_j_jhep_2019_03_001 crossref_primary_10_3390_jcm14031034 crossref_primary_10_1038_s41598_022_10608_y crossref_primary_10_1111_1751_2980_12911 crossref_primary_10_1111_apt_15245 crossref_primary_10_1080_17425255_2024_2398628 crossref_primary_10_3390_cancers16122196 crossref_primary_10_2196_11234 crossref_primary_10_1111_hepr_13460 crossref_primary_10_1136_gutjnl_2023_331695 crossref_primary_10_1016_j_heliyon_2023_e22605 crossref_primary_10_1093_ajhp_zxaa365 crossref_primary_10_1007_s11938_021_00346_x crossref_primary_10_1016_j_jceh_2023_05_009 crossref_primary_10_1007_s10147_020_01698_7 crossref_primary_10_1080_09537104_2019_1704715 crossref_primary_10_1111_liv_15464 crossref_primary_10_1200_JCO_20_02672 crossref_primary_10_3390_cancers17060972 crossref_primary_10_1016_S0140_6736_22_01200_4 crossref_primary_10_1159_000486763 crossref_primary_10_1016_S2468_1253_23_00147_4 crossref_primary_10_1177_17588359251323199 crossref_primary_10_18632_oncotarget_21528 crossref_primary_10_1590_s0004_2803_202000000_20 crossref_primary_10_2217_fon_2020_0323 crossref_primary_10_1159_000496439 crossref_primary_10_1016_j_aohep_2023_101185 crossref_primary_10_2478_raon_2020_0027 crossref_primary_10_1007_s11605_022_05469_9 crossref_primary_10_1016_j_coph_2021_07_009 crossref_primary_10_1111_hepr_13294 crossref_primary_10_1097_HEP_0000000000000452 crossref_primary_10_1111_apt_15789 crossref_primary_10_1097_HEP_0000000000000572 crossref_primary_10_1055_a_2446_2408 crossref_primary_10_7717_peerj_15950 crossref_primary_10_1001_jamaoncol_2023_2677 crossref_primary_10_1016_j_dld_2022_07_003 crossref_primary_10_3727_105221620X15880179864121 crossref_primary_10_1200_OP_20_00443 crossref_primary_10_1080_14728214_2025_2456774 crossref_primary_10_1002_jcp_28019 crossref_primary_10_1016_j_coph_2023_102365 crossref_primary_10_1159_000520095 crossref_primary_10_2217_fon_2017_0166 crossref_primary_10_1002_ijc_32964 crossref_primary_10_1055_a_2189_8461 crossref_primary_10_3348_kjr_2019_0140 crossref_primary_10_1097_HEP_0000000000000466 crossref_primary_10_1111_ajco_13454 crossref_primary_10_3390_cancers12123830 crossref_primary_10_2139_ssrn_3972354 crossref_primary_10_1002_cam4_5224 crossref_primary_10_1038_s41598_018_28337_6 crossref_primary_10_2217_fon_2019_0287 crossref_primary_10_1007_s10637_018_0621_x crossref_primary_10_4251_wjgo_v13_i12_2038 crossref_primary_10_1186_s12885_022_09453_z crossref_primary_10_1634_theoncologist_2019_0718 crossref_primary_10_3389_fendo_2024_1415488 crossref_primary_10_1093_oncolo_oyad110 crossref_primary_10_1016_j_clon_2022_04_012 crossref_primary_10_1111_liv_15813 crossref_primary_10_1200_OP_24_00872 crossref_primary_10_3138_canlivj_2022_0001 crossref_primary_10_2217_hep_2017_0020 crossref_primary_10_1016_j_jhep_2021_11_013 crossref_primary_10_1097_SLA_0000000000005373 crossref_primary_10_1007_s12254_020_00590_4 crossref_primary_10_1111_apt_14913 crossref_primary_10_2147_JHC_S422300 crossref_primary_10_1053_j_gastro_2017_04_029 crossref_primary_10_1186_s12885_018_4144_9 crossref_primary_10_1016_j_jhep_2024_01_018 crossref_primary_10_2147_JHC_S358082 crossref_primary_10_2147_JHC_S270532 crossref_primary_10_1016_j_acra_2023_05_014 crossref_primary_10_1177_17562848221086126 crossref_primary_10_1097_MD_0000000000035713 crossref_primary_10_1007_s12072_020_10120_3 crossref_primary_10_1080_14737140_2023_2183844 crossref_primary_10_3233_CBM_220042 crossref_primary_10_3389_fonc_2021_637971 crossref_primary_10_1053_j_semdp_2016_12_011 crossref_primary_10_3348_kjr_2022_0822 crossref_primary_10_1080_14656566_2017_1378346 crossref_primary_10_1200_EDBK_237555 crossref_primary_10_1002_hep_32468 crossref_primary_10_1055_a_2189_8567 crossref_primary_10_4103_sjg_SJG_477_20 crossref_primary_10_1002_mco2_474 crossref_primary_10_23736_S2724_5985_20_02775_0 crossref_primary_10_1097_MD_0000000000009757 crossref_primary_10_1016_j_jhep_2018_03_019 crossref_primary_10_2217_fon_2020_0758 crossref_primary_10_1002_hep_29515 crossref_primary_10_1080_14656566_2018_1479398 crossref_primary_10_1080_13543784_2021_1940948 crossref_primary_10_3748_wjg_v29_i10_1407 crossref_primary_10_3390_cancers13246310 crossref_primary_10_2147_JHC_S413283 crossref_primary_10_3390_biomedicines12071432 crossref_primary_10_1002_hep4_1481 crossref_primary_10_1080_14656566_2021_1892074 crossref_primary_10_12998_wjcc_v6_i5_74 crossref_primary_10_1200_GO_23_00215 crossref_primary_10_1159_000525582 crossref_primary_10_1038_s41392_020_00264_x crossref_primary_10_1097_MD_0000000000021191 crossref_primary_10_1159_000499765 crossref_primary_10_1007_s00228_024_03718_1 crossref_primary_10_1016_j_ctrv_2019_101946 crossref_primary_10_1016_j_ejso_2020_03_210 crossref_primary_10_1016_j_jhep_2018_03_028 crossref_primary_10_1111_liv_14436 crossref_primary_10_1055_s_0040_1719186 crossref_primary_10_1055_a_2189_8826 crossref_primary_10_1055_a_1226_3047 crossref_primary_10_1080_14737140_2018_1524297 crossref_primary_10_1186_s12944_022_01716_9 crossref_primary_10_3390_cancers16234059 crossref_primary_10_1186_s13014_023_02232_5 crossref_primary_10_3390_biomedicines10123202 crossref_primary_10_1007_s40801_021_00245_8 crossref_primary_10_2174_1389450122666210412125018 crossref_primary_10_1016_j_jhep_2019_08_015 crossref_primary_10_1038_s41416_021_01577_6 crossref_primary_10_1097_MOG_0000000000000626 crossref_primary_10_1016_j_tranon_2021_101153 crossref_primary_10_1111_hepr_13196 crossref_primary_10_1002_cam4_4906 crossref_primary_10_1016_S1470_2045_16_30569_1 crossref_primary_10_1002_lci2_38 crossref_primary_10_3748_wjg_v25_i28_3704 crossref_primary_10_1007_s00761_018_0404_1 crossref_primary_10_1055_a_2460_6298 crossref_primary_10_2147_JHC_S432948 crossref_primary_10_1055_a_2026_1277 crossref_primary_10_1007_s15036_023_3327_7 crossref_primary_10_3390_cancers15174345 crossref_primary_10_1055_a_1589_7568 crossref_primary_10_1016_j_ctrv_2018_05_006 crossref_primary_10_3390_medicina59081427 crossref_primary_10_1038_s41571_018_0073_4 crossref_primary_10_1007_s12328_021_01506_3 crossref_primary_10_37174_2587_7593_2021_4_1_42_52 crossref_primary_10_1159_000541622 crossref_primary_10_1080_14737159_2022_2049248 crossref_primary_10_1111_liv_15504 crossref_primary_10_1200_JCO_23_02745 crossref_primary_10_3390_cancers14164028 crossref_primary_10_3350_cmh_2022_0294 crossref_primary_10_1002_ijc_30804 crossref_primary_10_3390_cancers16010051 crossref_primary_10_1002_ueg2_12626 crossref_primary_10_14218_JCTH_2017_00002 crossref_primary_10_17998_jlc_2022_11_07 crossref_primary_10_1002_hep_30521 crossref_primary_10_1007_s00330_020_07171_3 crossref_primary_10_3748_wjg_v29_i10_1551 crossref_primary_10_4166_kjg_2020_75_3_147 crossref_primary_10_3390_medicina55100707 crossref_primary_10_3390_cancers16223829 crossref_primary_10_1080_17425255_2023_2272598 crossref_primary_10_5009_gnl220406 crossref_primary_10_1007_s10238_023_01014_3 crossref_primary_10_1136_bmj_m3544 crossref_primary_10_1016_j_cld_2024_08_010 crossref_primary_10_1111_apt_17441 crossref_primary_10_1016_j_jhep_2021_04_047 crossref_primary_10_1007_s11864_023_01135_7 crossref_primary_10_3390_cancers11060861 crossref_primary_10_1016_j_dld_2024_01_199 crossref_primary_10_3350_cmh_2023_0114 crossref_primary_10_1002_cncr_32697 crossref_primary_10_3390_cancers16071388 crossref_primary_10_1080_0284186X_2018_1479070 crossref_primary_10_2217_fon_2020_1004 crossref_primary_10_3389_fonc_2021_751159 crossref_primary_10_3390_ijms24021681 crossref_primary_10_1200_CCI_23_00220 crossref_primary_10_2147_JHC_S224938 crossref_primary_10_3748_wjg_v24_i36_4152 crossref_primary_10_1007_s15004_021_8778_4 crossref_primary_10_1159_000501749 crossref_primary_10_3389_fonc_2022_821903 crossref_primary_10_1055_a_2026_1240 crossref_primary_10_1159_000502714 crossref_primary_10_16931_1995_5464_2020227_38 crossref_primary_10_1002_cam4_6033 crossref_primary_10_1177_17588359221080298 crossref_primary_10_1002_cncr_32206 crossref_primary_10_1245_s10434_017_5989_x crossref_primary_10_3390_cancers14030768 crossref_primary_10_1159_000493586 crossref_primary_10_1177_17588359221148541 crossref_primary_10_1159_000507022 crossref_primary_10_1016_j_pharmthera_2017_07_006 crossref_primary_10_1080_0284186X_2020_1759826 crossref_primary_10_1080_14737140_2019_1559058 crossref_primary_10_1055_a_1589_7520 crossref_primary_10_1097_MCG_0000000000001085 crossref_primary_10_3748_wjg_v25_i29_3870 crossref_primary_10_1016_j_ejca_2018_09_031 crossref_primary_10_1200_EDBK_430028 crossref_primary_10_1097_HEP_0000000000000030 crossref_primary_10_3748_wjg_v27_i24_3429 crossref_primary_10_1016_j_dld_2019_06_015 crossref_primary_10_1002_cam4_6046 crossref_primary_10_3390_cancers13112677 crossref_primary_10_26442_20751753_2023_6_202351 crossref_primary_10_3390_cancers15174423 crossref_primary_10_1111_jcmm_15090 crossref_primary_10_1002_lci2_62 crossref_primary_10_1007_s41971_020_00080_8 crossref_primary_10_1016_j_semradonc_2018_06_006 crossref_primary_10_1590_1806_9282_66_3_275 crossref_primary_10_1016_j_jhep_2024_08_028 crossref_primary_10_4251_wjgo_v15_i10_1796 crossref_primary_10_1007_s10620_021_07365_9 crossref_primary_10_2217_fon_2021_0457 crossref_primary_10_1186_s12967_024_05726_2 crossref_primary_10_2174_1871520622666220425124419 crossref_primary_10_1159_000515551 crossref_primary_10_2217_fon_2019_0658 crossref_primary_10_1007_s00261_021_03065_0 crossref_primary_10_1159_000508901 crossref_primary_10_3390_cancers14071747 crossref_primary_10_1159_000537686 crossref_primary_10_1159_000497161 crossref_primary_10_1111_liv_14573 crossref_primary_10_1080_17474124_2024_2442573 crossref_primary_10_2147_JHC_S268293 crossref_primary_10_1159_000507381 crossref_primary_10_1177_17588359221097934 crossref_primary_10_3390_cancers13153758 crossref_primary_10_1080_2162402X_2023_2214478 crossref_primary_10_1016_j_jceh_2019_07_012 |
| Cites_doi | 10.1016/S1470-2045(08)70285-7 10.1002/bjs.1800600817 10.1111/j.1742-1241.2010.02414.x 10.1056/NEJMoa0708857 10.1016/S1001-9294(14)60017-1 10.1200/JCO.2008.20.0931 10.3892/mco.2015.536 10.1097/MEG.0b013e3283386053 10.1016/j.cgh.2015.08.014 10.1002/hep.25637 10.1053/j.seminoncol.2014.01.001 10.4254/wjh.v6.i9.670 10.1002/hep.24199 10.1002/14651858.CD001199.pub2 10.1111/j.1365-2036.2011.04860.x 10.1111/j.1872-034X.2012.00991.x 10.1093/annonc/mds343 10.1200/jco.2011.29.15_suppl.2580 10.1097/MEG.0b013e328333df23 10.1200/jco.2011.29.15_suppl.4083 10.1007/s00280-011-1616-x 10.1200/JCO.2014.57.9151 10.1093/annonc/mdt055 10.5414/CP201907 10.3322/caac.21262 10.3748/wjg.v21.i28.8478 |
| ContentType | Journal Article |
| Copyright | 2016 European Association for the Study of the Liver Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Copyright Elsevier Science Ltd. Dec 2016 |
| Copyright_xml | – notice: 2016 European Association for the Study of the Liver – notice: Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Science Ltd. Dec 2016 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 ADTOC UNPAY |
| DOI | 10.1016/j.jhep.2016.07.020 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1600-0641 |
| EndPage | 1147 |
| ExternalDocumentID | 10.1016/j.jhep.2016.07.020 27469901 10_1016_j_jhep_2016_07_020 S0168827816303464 1_s2_0_S0168827816303464 |
| Genre | Journal Article Observational Study |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU LCYCR AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c600t-932c181edb9cde0cc21b328305f88c3797778ac60304b70eaeb7aa2d4e1216383 |
| IEDL.DBID | UNPAY |
| ISSN | 0168-8278 1600-0641 |
| IngestDate | Tue Aug 19 19:42:09 EDT 2025 Sat Sep 27 21:26:39 EDT 2025 Sun Jul 13 04:20:25 EDT 2025 Mon Jul 21 05:45:09 EDT 2025 Wed Oct 01 03:03:08 EDT 2025 Thu Apr 24 23:03:17 EDT 2025 Fri Feb 23 02:32:17 EST 2024 Tue Feb 25 20:02:31 EST 2025 Tue Oct 14 19:35:31 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | ECOG PS Child-Pugh TNM AE CI Sorafenib BCLC HCC Hepatocellular carcinoma INR GIDEON Nexavar sorafenib adverse event international normalized ratio Eastern Cooperative Oncology Group performance status Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib tumor node metastasis confidence interval Barcelona Clinic Liver Cancer hepatocellular carcinoma |
| Language | English |
| License | Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c600t-932c181edb9cde0cc21b328305f88c3797778ac60304b70eaeb7aa2d4e1216383 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=http://www.journal-of-hepatology.eu/article/S0168827816303464/pdf |
| PMID | 27469901 |
| PQID | 2078813395 |
| PQPubID | 2047556 |
| PageCount | 8 |
| ParticipantIDs | unpaywall_primary_10_1016_j_jhep_2016_07_020 proquest_miscellaneous_1826737721 proquest_journals_2078813395 pubmed_primary_27469901 crossref_primary_10_1016_j_jhep_2016_07_020 crossref_citationtrail_10_1016_j_jhep_2016_07_020 elsevier_sciencedirect_doi_10_1016_j_jhep_2016_07_020 elsevier_clinicalkeyesjournals_1_s2_0_S0168827816303464 elsevier_clinicalkey_doi_10_1016_j_jhep_2016_07_020 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-12-01 |
| PublicationDateYYYYMMDD | 2016-12-01 |
| PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Amsterdam |
| PublicationTitle | Journal of hepatology |
| PublicationTitleAlternate | J Hepatol |
| PublicationYear | 2016 |
| Publisher | Elsevier B.V Elsevier Science Ltd |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd |
| References | Cheng, Kang, Chen, Tsao, Qin, Kim (b0035) 2009; 10 Bayer Pharma AG. Nexavar® (sorafenib). Summary of product characteristics. Available from Peck-Radosavljevic, Greten, Lammer, Rosmorduc, Sangro, Santoro (b0045) 2010; 22 Bettinger, Schultheiß, Knüppel, Thimme, Blum, Spangenberg (b0160) 2012; 56 Kim, Ryoo, Ryu, Chang, Suh, Lee (b0075) 2011; 68 Hollebecque, Cattan, Romano, Sergent, Mourad, Louvet (b0070) 2011; 34 Pressiani, Boni, Rimassa, Labianca, Fagiuoli, Salvagni (b0120) 2013; 24 Otsuka, Eguchi, Kawazoe, Yanagita, Ario, Kitahara (b0145) 2012; 42 Llovet, Ricci, Mazzaferro, Hilgard, Gane, Blanc (b0030) 2008; 359 Chiu, Tang, Yao, Wong, Wong, Leung (b0130) 2011; 29 Lettieri, Mazzu, Huang, Lathia (b0105) 2011; 29 Di Marco, De Vita, Koskinas, Semela, Toniutto, Verslype (b0125) 2013; 24 Pugh, Murray-Lyon, Dawson, Pietroni, Williams (b0060) 1973; 60 Ozenne, Paradis, Pernot, Castelnau, Vullierme, Bouattour (b0065) 2010; 22 Bruix, Sherman (b0040) 2011; 53 Torre, Bray, Siegel, Ferlay, Lortet-Tieulent, Jemal (b0005) 2015; 65 Johnson, Berhane, Kagebayashi, Satomura, Teng, Reeves (b0140) 2015; 33 Brose, Frenette, Keefe, Stein (b0090) 2014; 41 da Fonseca, Barroso-Sousa, Bento, Blanco, Valente, Pfiffer (b0085) 2015; 3 Miller, Murry, Owzar, Hollis, Kennedy, Abou-Alfa (b0100) 2009; 27 Singal, El-Serag (b0015) 2015; 13 Samuel, Chow, Chan Shih-Yen, Machin, Soo (b0020) 2009 European Medicines Agency. EUDRALEX: The rules governing medicinal products in the European Union. Available from Abou-Alfa, Amadori, Santoro, Figer, De Greve, Lathia (b0095) 2011; 4 Shomura, Kagawa, Shiraishi, Hirose, Arase, Koizumi (b0155) 2014; 6 Al-Rajabi, Patel, Ketchum, Jaime, Lu, Pollock (b0080) 2015; 6 Ji, Zhang, Lan, Nie, Geng, Liu (b0135) 2014; 29 Schlachterman, Craft, Hilgenfeldt, Mitra, Cabrera (b0025) 2015; 21 Mitchell DY, Prins K, Ploeger B, Grevel J, Lettieri J, Meinhardt G, et al. Impact of Child-Pugh status (A, B, or C) and duration of treatment on sorafenib exposure in patients with advanced hepatocellular carcinoma in the Phase IV HATT trial: a population pharmacokinetic analysis (abstract O-030). International Liver Cancer Association, Kyoto, Japan, 5–7 September, 2014. Accessed 5 November 2015. Lencioni, Marrero, Venook, Ye, Kudo (b0050) 2010; 64 Shin, Lee (b0150) 2013; 51 Monsour, Asham, McFadden, Victor, Muthuswamy, Zaheer (b0010) 2013; 2 Peck-Radosavljevic (10.1016/j.jhep.2016.07.020_b0045) 2010; 22 da Fonseca (10.1016/j.jhep.2016.07.020_b0085) 2015; 3 Miller (10.1016/j.jhep.2016.07.020_b0100) 2009; 27 Samuel (10.1016/j.jhep.2016.07.020_b0020) 2009 Johnson (10.1016/j.jhep.2016.07.020_b0140) 2015; 33 Bruix (10.1016/j.jhep.2016.07.020_b0040) 2011; 53 Lettieri (10.1016/j.jhep.2016.07.020_b0105) 2011; 29 Pugh (10.1016/j.jhep.2016.07.020_b0060) 1973; 60 10.1016/j.jhep.2016.07.020_b0055 10.1016/j.jhep.2016.07.020_b0110 10.1016/j.jhep.2016.07.020_b0115 Monsour (10.1016/j.jhep.2016.07.020_b0010) 2013; 2 Ozenne (10.1016/j.jhep.2016.07.020_b0065) 2010; 22 Pressiani (10.1016/j.jhep.2016.07.020_b0120) 2013; 24 Shin (10.1016/j.jhep.2016.07.020_b0150) 2013; 51 Abou-Alfa (10.1016/j.jhep.2016.07.020_b0095) 2011; 4 Chiu (10.1016/j.jhep.2016.07.020_b0130) 2011; 29 Brose (10.1016/j.jhep.2016.07.020_b0090) 2014; 41 Lencioni (10.1016/j.jhep.2016.07.020_b0050) 2010; 64 Singal (10.1016/j.jhep.2016.07.020_b0015) 2015; 13 Hollebecque (10.1016/j.jhep.2016.07.020_b0070) 2011; 34 Kim (10.1016/j.jhep.2016.07.020_b0075) 2011; 68 Bettinger (10.1016/j.jhep.2016.07.020_b0160) 2012; 56 Al-Rajabi (10.1016/j.jhep.2016.07.020_b0080) 2015; 6 Schlachterman (10.1016/j.jhep.2016.07.020_b0025) 2015; 21 Torre (10.1016/j.jhep.2016.07.020_b0005) 2015; 65 Llovet (10.1016/j.jhep.2016.07.020_b0030) 2008; 359 Shomura (10.1016/j.jhep.2016.07.020_b0155) 2014; 6 Ji (10.1016/j.jhep.2016.07.020_b0135) 2014; 29 Otsuka (10.1016/j.jhep.2016.07.020_b0145) 2012; 42 Cheng (10.1016/j.jhep.2016.07.020_b0035) 2009; 10 Di Marco (10.1016/j.jhep.2016.07.020_b0125) 2013; 24 |
| References_xml | – volume: 29 start-page: abs2580 year: 2011 ident: b0105 article-title: Effect of hepatic impairment on sorafenib pharmacokinetics: results of a multicenter, open-label, single-dose, phase I trial publication-title: J Clin Oncol – volume: 24 start-page: 406 year: 2013 end-page: 411 ident: b0120 article-title: Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis publication-title: Ann Oncol – volume: 34 start-page: 1193 year: 2011 end-page: 1201 ident: b0070 article-title: Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score publication-title: Aliment Pharmacol Ther – reference: Bayer Pharma AG. Nexavar® (sorafenib). Summary of product characteristics. Available from: – volume: 33 start-page: 550 year: 2015 end-page: 558 ident: b0140 article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade publication-title: J Clin Oncol – volume: 6 start-page: 670 year: 2014 end-page: 676 ident: b0155 article-title: Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma publication-title: World J Hepatol – volume: 60 start-page: 646 year: 1973 end-page: 649 ident: b0060 article-title: Transection of the oesophagus for bleeding oesophageal varices publication-title: Br J Surg – volume: 22 start-page: 391 year: 2010 end-page: 398 ident: b0045 article-title: Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma publication-title: Eur J Gastroenterol Hepatol – volume: 359 start-page: 378 year: 2008 end-page: 390 ident: b0030 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med – volume: 64 start-page: 1034 year: 2010 end-page: 1041 ident: b0050 article-title: Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study publication-title: Int J Clin Pract – year: 2009 ident: b0020 article-title: Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma publication-title: Cochrane Database Syst Rev – volume: 29 start-page: 7 year: 2014 end-page: 14 ident: b0135 article-title: Sorafenib in liver function impaired advanced hepatocellular carcinoma publication-title: Chin Med Sci J – volume: 51 start-page: 837 year: 2013 end-page: 846 ident: b0150 article-title: Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib publication-title: Int J Clin Pharmacol Ther – reference: European Medicines Agency. EUDRALEX: The rules governing medicinal products in the European Union. Available from: – volume: 56 start-page: 789 year: 2012 ident: b0160 article-title: Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma publication-title: Hepatology – volume: 65 start-page: 87 year: 2015 end-page: 108 ident: b0005 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J Clin – volume: 68 start-page: 1285 year: 2011 end-page: 1290 ident: b0075 article-title: Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function publication-title: Cancer Chemother Pharmacol – volume: 24 start-page: ii30 year: 2013 end-page: ii37 ident: b0125 article-title: Sorafenib: from literature to clinical practice publication-title: Ann Oncol – volume: 4 start-page: 40 year: 2011 end-page: 44 ident: b0095 article-title: Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A publication-title: Gastrointest Cancer Res – volume: 3 start-page: 793 year: 2015 end-page: 796 ident: b0085 article-title: Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma publication-title: Mol Clin Oncol – volume: 27 start-page: 1800 year: 2009 end-page: 1805 ident: b0100 article-title: Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 publication-title: J Clin Oncol – volume: 42 start-page: 879 year: 2012 end-page: 886 ident: b0145 article-title: Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib publication-title: Hepatol Res – volume: 13 start-page: 2140 year: 2015 end-page: 2151 ident: b0015 article-title: Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice publication-title: Clin Gastroenterol Hepatol – reference: Mitchell DY, Prins K, Ploeger B, Grevel J, Lettieri J, Meinhardt G, et al. Impact of Child-Pugh status (A, B, or C) and duration of treatment on sorafenib exposure in patients with advanced hepatocellular carcinoma in the Phase IV HATT trial: a population pharmacokinetic analysis (abstract O-030). International Liver Cancer Association, Kyoto, Japan, 5–7 September, 2014. – volume: 53 start-page: 1020 year: 2011 end-page: 1022 ident: b0040 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology – volume: 29 start-page: abs4083 year: 2011 ident: b0130 article-title: The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis publication-title: J Clin Oncol – volume: 2 start-page: 492 year: 2013 end-page: 506 ident: b0010 article-title: Hepatocellular carcinoma: the rising tide from east to west—review of epidemiology, screening and tumor markers publication-title: Transl Cancer Res – volume: 10 start-page: 25 year: 2009 end-page: 34 ident: b0035 article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial publication-title: Lancet Oncol – reference: . Accessed 5 November 2015. – volume: 41 start-page: S1 year: 2014 end-page: S16 ident: b0090 article-title: Management of sorafenib-related adverse events: a clinician’s perspective publication-title: Semin Oncol – volume: 21 start-page: 8478 year: 2015 end-page: 8491 ident: b0025 article-title: Current and future treatments for hepatocellular carcinoma publication-title: World J Gastroenterol – volume: 22 start-page: 1106 year: 2010 end-page: 1110 ident: b0065 article-title: Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib publication-title: Eur J Gastroenterol Hepatol – volume: 6 start-page: 259 year: 2015 end-page: 267 ident: b0080 article-title: Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction publication-title: J Gastrointest Oncol – ident: 10.1016/j.jhep.2016.07.020_b0115 – volume: 10 start-page: 25 year: 2009 ident: 10.1016/j.jhep.2016.07.020_b0035 article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70285-7 – volume: 60 start-page: 646 year: 1973 ident: 10.1016/j.jhep.2016.07.020_b0060 article-title: Transection of the oesophagus for bleeding oesophageal varices publication-title: Br J Surg doi: 10.1002/bjs.1800600817 – volume: 64 start-page: 1034 year: 2010 ident: 10.1016/j.jhep.2016.07.020_b0050 article-title: Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2010.02414.x – volume: 359 start-page: 378 year: 2008 ident: 10.1016/j.jhep.2016.07.020_b0030 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 – volume: 29 start-page: 7 year: 2014 ident: 10.1016/j.jhep.2016.07.020_b0135 article-title: Sorafenib in liver function impaired advanced hepatocellular carcinoma publication-title: Chin Med Sci J doi: 10.1016/S1001-9294(14)60017-1 – volume: 27 start-page: 1800 year: 2009 ident: 10.1016/j.jhep.2016.07.020_b0100 article-title: Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.0931 – volume: 3 start-page: 793 year: 2015 ident: 10.1016/j.jhep.2016.07.020_b0085 article-title: Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma publication-title: Mol Clin Oncol doi: 10.3892/mco.2015.536 – volume: 6 start-page: 259 year: 2015 ident: 10.1016/j.jhep.2016.07.020_b0080 article-title: Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction publication-title: J Gastrointest Oncol – volume: 22 start-page: 1106 year: 2010 ident: 10.1016/j.jhep.2016.07.020_b0065 article-title: Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e3283386053 – volume: 13 start-page: 2140 year: 2015 ident: 10.1016/j.jhep.2016.07.020_b0015 article-title: Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.08.014 – volume: 56 start-page: 789 year: 2012 ident: 10.1016/j.jhep.2016.07.020_b0160 article-title: Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.25637 – volume: 41 start-page: S1 year: 2014 ident: 10.1016/j.jhep.2016.07.020_b0090 article-title: Management of sorafenib-related adverse events: a clinician’s perspective publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2014.01.001 – ident: 10.1016/j.jhep.2016.07.020_b0055 – volume: 6 start-page: 670 year: 2014 ident: 10.1016/j.jhep.2016.07.020_b0155 article-title: Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma publication-title: World J Hepatol doi: 10.4254/wjh.v6.i9.670 – volume: 53 start-page: 1020 year: 2011 ident: 10.1016/j.jhep.2016.07.020_b0040 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology doi: 10.1002/hep.24199 – year: 2009 ident: 10.1016/j.jhep.2016.07.020_b0020 article-title: Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD001199.pub2 – volume: 34 start-page: 1193 year: 2011 ident: 10.1016/j.jhep.2016.07.020_b0070 article-title: Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2011.04860.x – volume: 42 start-page: 879 year: 2012 ident: 10.1016/j.jhep.2016.07.020_b0145 article-title: Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib publication-title: Hepatol Res doi: 10.1111/j.1872-034X.2012.00991.x – ident: 10.1016/j.jhep.2016.07.020_b0110 – volume: 24 start-page: 406 year: 2013 ident: 10.1016/j.jhep.2016.07.020_b0120 article-title: Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis publication-title: Ann Oncol doi: 10.1093/annonc/mds343 – volume: 29 start-page: abs2580 year: 2011 ident: 10.1016/j.jhep.2016.07.020_b0105 article-title: Effect of hepatic impairment on sorafenib pharmacokinetics: results of a multicenter, open-label, single-dose, phase I trial publication-title: J Clin Oncol doi: 10.1200/jco.2011.29.15_suppl.2580 – volume: 22 start-page: 391 year: 2010 ident: 10.1016/j.jhep.2016.07.020_b0045 article-title: Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e328333df23 – volume: 29 start-page: abs4083 year: 2011 ident: 10.1016/j.jhep.2016.07.020_b0130 article-title: The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis publication-title: J Clin Oncol doi: 10.1200/jco.2011.29.15_suppl.4083 – volume: 2 start-page: 492 year: 2013 ident: 10.1016/j.jhep.2016.07.020_b0010 article-title: Hepatocellular carcinoma: the rising tide from east to west—review of epidemiology, screening and tumor markers publication-title: Transl Cancer Res – volume: 68 start-page: 1285 year: 2011 ident: 10.1016/j.jhep.2016.07.020_b0075 article-title: Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-011-1616-x – volume: 33 start-page: 550 year: 2015 ident: 10.1016/j.jhep.2016.07.020_b0140 article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade publication-title: J Clin Oncol doi: 10.1200/JCO.2014.57.9151 – volume: 24 start-page: ii30 year: 2013 ident: 10.1016/j.jhep.2016.07.020_b0125 article-title: Sorafenib: from literature to clinical practice publication-title: Ann Oncol doi: 10.1093/annonc/mdt055 – volume: 51 start-page: 837 year: 2013 ident: 10.1016/j.jhep.2016.07.020_b0150 article-title: Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CP201907 – volume: 65 start-page: 87 year: 2015 ident: 10.1016/j.jhep.2016.07.020_b0005 article-title: Global cancer statistics, 2012 publication-title: CA Cancer J Clin doi: 10.3322/caac.21262 – volume: 4 start-page: 40 year: 2011 ident: 10.1016/j.jhep.2016.07.020_b0095 article-title: Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A vs. B cirrhosis publication-title: Gastrointest Cancer Res – volume: 21 start-page: 8478 year: 2015 ident: 10.1016/j.jhep.2016.07.020_b0025 article-title: Current and future treatments for hepatocellular carcinoma publication-title: World J Gastroenterol doi: 10.3748/wjg.v21.i28.8478 |
| SSID | ssj0003094 |
| Score | 2.6327317 |
| Snippet | [Display omitted]
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective,... Graphical abstract GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry... Background & Aims: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective,... |
| SourceID | unpaywall proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1140 |
| SubjectTerms | Antineoplastic Agents Carcinoma, Hepatocellular Child Child-Pugh Clinical medicine Drug therapy Gastroenterology and Hepatology GIDEON HCC Hepatocellular carcinoma Humans Liver cancer Liver diseases Liver Neoplasms Medical treatment Nexavar Niacinamide - analogs & derivatives Niacinamide - therapeutic use Patient handling Patients Phenylurea Compounds - therapeutic use Prospective Studies Registries Safety Sorafenib |
| SummonAdditionalLinks | – databaseName: ScienceDirect (Elsevier) dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9Ne-DjAfFNYCAj8Qahju3GKW9obAykbUgwaW-W7ThbqyqtSCPEC387d4kTQJsGQupLW1t27s727-K73wG8mCmhKkdXg86jg-IcLikl0XF1QZSCO1t1xSYOj_KDE_XxdHq6BbtDLgyFVca9v9_Tu906_jKJ0pys5_PJZwQrCA91gYiCS5UTJ6hSmqoYvP7xK8xD8lnk9y5Sah0TZ_oYr8V5IM7KrCfwpJrflx9OF8HnTbje1mv7_ZtdLn87kPZvw62IJNnbfrJ3YCvUd-HaYbwrvweLYze-ccV2VIGBCruxVcUa1HsV6rljbRPYvGZDfiQbkqaY7WbIOubj9FN7ds6a1nUpIM0bhrbF3n94t3d8xDp62vtwsr_3ZfcgjZUVUo8AZ5MiaPN4tIfSzXwZuPcic5KowKZVUXipERTqwmJbyZXTPNjgtLWiVCETBODkA9iuV3V4BMyGQnn8VCX6ijk6vFZWtgyFs1mRq6pIIBtEanykHafqF0szxJctDKnBkBoM1wbVkMDLsc-6J924srUcNGUGceEGaPBMuLKXvqxXaOIabkxmGmG4uWBnCUzHnn-Y6l9H3BnMyIyDCE58_lLOpgk8H__GJU73NrYOqxYngi6glugGZQk87M1vFIvQKqerzQRejfb4DzJ7_J_P8ARu0Lc-nmcHtjdf2_AUUdnGPeuW3U_WjzKg priority: 102 providerName: Elsevier |
| Title | Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0168827816303464 https://www.clinicalkey.es/playcontent/1-s2.0-S0168827816303464 https://dx.doi.org/10.1016/j.jhep.2016.07.020 https://www.ncbi.nlm.nih.gov/pubmed/27469901 https://www.proquest.com/docview/2078813395 https://www.proquest.com/docview/1826737721 http://www.journal-of-hepatology.eu/article/S0168827816303464/pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 65 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1600-0641 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003094 issn: 1600-0641 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect customDbUrl: eissn: 1600-0641 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003094 issn: 1600-0641 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1600-0641 dateEnd: 20210630 omitProxy: true ssIdentifier: ssj0003094 issn: 1600-0641 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1600-0641 dateEnd: 20210630 omitProxy: true ssIdentifier: ssj0003094 issn: 1600-0641 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1600-0641 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003094 issn: 1600-0641 databaseCode: AKRWK dateStart: 19850101 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwED-xVuLxgfcjMCoj8Q3SJrGbpHyrxkYHrKuASvDJsh2brVRpRRqh8YG_nXPiRJM6jYcUKYpylpO7i_273Avg-YhFzEjrGpQKDRQp8ZNiFA1XqaMsCqQwVbOJo2k8mbO3n4fnogltVKVjor8y_gkuyVUb17O-LgeOl4OPCFMQGCYpYomAspgN1pnZgW48RDjege58Oht_qWt6p76ls0ZXbDOoYxa6xJk6xmuBE9jwrrqAp-35ffHmtA0-b8C1Ml-Lsx9iuTy3IR3cAtmk9dRxKN_65Ub21c_tKo___6634aaDq2Rc092BKzq_C1ePnEP-HiyOZftbF-lsmwfbPY6sDClQuYzOTyUpC01Oc9IkYZImM4uIig2kKq_sz8qvJ6QoZZVnUrwiqMDkzeHr_eMpqWrg3of5wf6nvYnv2jf4Cpm98REZKsQPOpMjlelAqSiU1NYbG5o0VTRB5JmkAmlpwGQSaKFlIkSUMR1GFiXSB9DJV7l-BETolCk8TIYGaYxWtaBGZDqVIkxjZlIPwkZuXLna5rbFxpI3QWwLbmXNrax5kHCUtQcv2jHrurLHpdS0UQfesAtXWY4bz6WjkotG6cLJveAhLyIe8C0xezBsRzosVGOcP8642-gqbyeJAts0gNLR0INn7W1cR6xzSOR6VeKDoJ2ZULS1Qg8e1jresiVKWGz9px68bJX-L3j2-N_In8B1e1XHCu1CZ_O91E8R8W1kD3b6v8IedMd7H97P7Pnw3WTac1_6b7h7VWo |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED6NIbHxgPi9bAOMxBuEOrYTp7yhsdHB2iGxSXuz7MRhraq0Io0mXvjbd06cANo0EFKeEltx7s72d_HddwCvhoKJwrijQZOhg2IMTinB0XE1luWMGl00xSbGk2R0Kj6dxWdrsNflwriwSr_2t2t6s1r7OwMvzcFyOh18RbCC8FCmiCgoF4m4BbdFzKTzwN7-_BXnwenQE3ynoWvuM2faIK_ZuXWklVHL4OmKfl-_O11Fn3dhoy6X-seFns9_25EO7sM9DyXJ-3a0D2DNlg_hztgflj-C2bHpf7liO1eCwVV2I4uCVKj4wpZTQ-rKkmlJugRJ0mVNEd2MkDTUx-GX-ts5qWrT5IBU7wgaF_l4-GH_eEIaftrHcHqwf7I3Cn1phTBDhLMKEbVluLfb3Ayz3NIsY5HhjgssLtI04xJRoUw1tuVUGEmttkZqzXJhI-YQHH8C6-WitFtAtE1FhleRo7OYoMereaFzmxodpYko0gCiTqQq87zjrvzFXHUBZjPl1KCcGhSVCtUQwOu-z7Jl3bixNe80pTpx4QqocFO4sZe8rpet_CSuVKQqpqi6YmgBxH3PP2z1r2_c7cxI9S9h1BH6cz6MA3jZP8Y57g5udGkXNQ4EfUDJ0Q-KAnjaml8vFiZF4s42A3jT2-M_yGz7P7_hBWyMTsZH6uhw8nkHNt2TNrhnF9ZX32v7DCHayjxvpuAlRO41ww |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9BJ8F44HsjMJCReIO0SezEKW8TbAykdZOgEjxZtmOzdVVakUZo--t3TpxoUqfxIeUlyllO7s7273JfAG_GLGFWOdeg0migKIVLilE0XJVJiiRS0jbNJg4n2cGUffmeXokmdFGVnonhwoYnuCU3bVzPh6YeeV6OviJMQWDIc8QSEWUZGy0Lexs2shTh-AA2ppPj3R9tTe88dHTO6MpcBnXGYp8408Z4zXACF97VFvB0Pb-vP5zWwec9uFuXS3n-W87nVw6k_QegurSeNg7lbFiv1FBfrFd5_P9vfQj3PVwluy3dI7hlysdw59A75J_A7Ej1v3WRzrV5cN3jyMKSCpXLmvJUkboy5LQkXRIm6TKziGzYQJryyuFx_fOEVLVq8kyq9wQVmHz6_HHvaEKaGrhPYbq_9-3DQejbN4Qamb0KERlqxA-mUGNdmEjrJFbU1RtLbZ5ryhF58lwiLY2Y4pGRRnEpk4KZOHEokW7BoFyU5hkQaXKm8bIFGqQZWtWSWlmYXMk4z5jNA4g7uQnta5u7Fhtz0QWxzYSTtXCyFhEXKOsA3vZjlm1ljxupaacOomMX7rICD54bR_HrRpnKy70SsagSEYk1MQeQ9iM9Fmoxzh9n3Ol0VfSTJJFrGkDpOA3gdf8Y9xHnHJKlWdT4Imhncoq2VhzAdqvjPVsSzjLnPw3gXa_0f8Gz5_9G_gI23V0bK7QDg9Wv2rxExLdSr_yavgSWclFJ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Observational+registry+of+sorafenib+use+in+clinical+practice+across+Child-Pugh+subgroups%3A+The+GIDEON+study&rft.jtitle=Journal+of+hepatology&rft.au=Marrero%2C+Jorge+A.&rft.au=Kudo%2C+Masatoshi&rft.au=Venook%2C+Alan+P.&rft.au=Ye%2C+Sheng-Long&rft.date=2016-12-01&rft.pub=Elsevier+B.V&rft.issn=0168-8278&rft.volume=65&rft.issue=6&rft.spage=1140&rft.epage=1147&rft_id=info:doi/10.1016%2Fj.jhep.2016.07.020&rft.externalDocID=S0168827816303464 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-8278&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-8278&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-8278&client=summon |